Breaking news on lymphoma, leukemia
Vion Pharmaceuticals Announces Initiation Of Clinical Trial Of Cloretazine(R) (VNP40101M) In Combination With Cytarabine published
Fri, 09 May 2008 00:00:00 PDT
VION PHARMACEUTICALS, INC. (Nasdaq: VION) announced the start of an investigator-sponsored Phase I/II clinical trial of its lead anticancer agent Cloretazine(R) (VNP40101M) in combination with cytarabine in elderly patients with previously untreated acute myelogenous leukemia (AML) and high-risk myelodysplastic syndromes (MDS). The trial is being conducted under the direction of Ellen K. Ritchie, M.D. at The Weill-Cornell Medical College in New York City.
Critical Outcome Technologies Inc. Announces Granting Of European Patents For Acute Myelogenous Leukemia Drug Candidates published
Thu, 08 May 2008 03:00:00 PDT
Critical Outcome Technologies Inc. (TSX VENTURE:COT), announced that patents to its novel drug candidates for the treatment of Acute Myelogenous Leukemia (AML) have recently been granted by the European Patent Office. The patents have been granted under European patent numbers 1 551 824 and 1 542 989 and provide protection in a market where approximately 18,000 new cases of AML are diagnosed each year and the trend in overall incidence of AML has been gradually increasing.
Risk Of Leukemia Relapse May Be Revealed By Molecular Change published
Thu, 01 May 2008 04:00:00 PDT
Researchers may have discovered a better way to distinguish acute leukemia patients who require aggressive treatment to prevent recurrence from those who need only standard therapy for cure.The study is published in the May 1 issue of the New England Journal of Medicine with an accompanying editorial.
New Analysis Finds Day Care Attendance Early In Life Cuts Childhood Leukaemia Risk By About 30% published
Tue, 29 Apr 2008 01:00:00 PDT
Children who attend day care or play groups have about a 30% lower risk of developing the most common type of childhood leukaemia than those who do not, according to a new analysis of studies investigating the link.
EU Approval For Zevalin(R) As First-Line Consolidation Treatment published
Tue, 29 Apr 2008 01:00:00 PDT
The European Commission has extended the marketing authorization for Zevalin® ([90Y]-ibritumomab tiuxetan) in Europe. Zevalin can now be used in the course of a first-line therapy after remission induction in previously untreated patients with follicular lymphoma. The aim of such a consolidation therapy is the improvement of the effect of an initial induction therapy. The benefit of Zevalin following rituximab in combination with chemotherapy has not been established.
Two Suppressor Molecules Affect 70 Genes In Leukemia published
Sun, 27 Apr 2008 07:00:00 PDT
By restoring two small molecules that are often lost in chronic leukemia, researchers were able to block tumor growth in an animal model.The research, using human chronic lymphocytic leukemia (CLL) cells, also showed that loss of the two molecules affects 70 genes, most of which are involved in critical functions such as cell growth, death, proliferation and metabolism.
90Y-ibritumomab Tiuxetan Safe And Effective For Non-Hodgkin's Lymphoma Patients After Chemotherapy published
Fri, 25 Apr 2008 00:00:00 PDT
Radioimmunotherapy using the radioactive drug yttrium-90 (90Y)ibritumomab tiuxetan following chemotherapy with fludarabine andmitoxantrone is feasible, well tolerated, and effective for follicularnon-Hodgkin's lymphoma (NHL) patients. This was published on March 13,2008 in The Lancet Oncology. Follicular lymphoma is cancer of the lymphocytes of the follicle centerB-lymphocytes.
One Of Nation's Largest Portfolios Of New Lymphoma Therapies Targets Diverse, Difficult Cancer published
Fri, 25 Apr 2008 00:00:00 PDT
The fifth leading cause of cancer in the United States, lymphoma is made up of more than 40 rare and highly diverse diseases that target the body's lymphatic system. Lymphomas include both one of the fastest growing cancers -- Burkitt's lymphoma, which can double in size in as little as a day -- and one of the slowest, chronic lymphocytic leukemia (CLL).
Immunicon Corporation Receives Grant To Develop Test For Residual Disease In Leukemia Patients published
Thu, 24 Apr 2008 02:00:00 PDT
Immunicon Corporation (NASDAQ CM:IMMC) announced today that the company received a four-year grant from the Center for Translational Molecular Medicine (CTMM) to develop a test to detect minimal residual disease in blood of Acute Myeloid Leukemia patients. Using current methods, detection can only be done by taking regular bone marrow aspirates, which are typically very painful to extract for the patient.
Risk Of Second Cancers Greatest In Younger Patients Treated For Non-Hodgkins Lymphoma published
Tue, 22 Apr 2008 01:00:00 PDT
For survivors of non-Hodgkin's lymphoma the risk of developing subsequent secondary cancers is greater the younger the patient's age at diagnosis, concludes a study published in the Journal of Clinical Oncology. The study also showed that the toll of subsequent solid tumours was largest 21 to 30 years after diagnosis.
Lymphoma - Free Patient Literature Now Available To All published
Mon, 21 Apr 2008 01:00:00 PDT
The Lymphoma Association is delighted to announce that all of their literature is now available to healthcare professionals free of charge. Since 1986 the charity has provided free literature to callers to the helpline. However, with immediate effect, the Association is now able to extend this provision to all areas of the medical community.
Experimental Drug Shows Promise In Treating One Class Of Lymphoma published
Sun, 20 Apr 2008 02:00:00 PDT
New clinical data showed some cancer patients with recurrent lymphoma benefited from an experimental drug called AME-133v, said a researcher at the University of Alabama at Birmingham (UAB).The data was presented during the 2008 annual meeting of the American Association for Cancer Research in San Diego.
ZIOPHARM Presents Positive Data From Phase II Study Of Darinaparsin In Advanced Hematological Malignancies At AACR 2008 Annual Meeting published
Fri, 18 Apr 2008 02:00:00 PDT
ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) announced that it presented positive data from a phase II study of darinaparsin, the Company's novel organic arsenic compound, in advanced hematological malignancies at the American Association for Cancer Research (AACR) Annual Meeting, in San Diego, CA.
Lymphoma Research Foundation Releases A New Mantle Cell Line - JeKo-1 Is Now Available From MCL Cell Bank published
Thu, 17 Apr 2008 02:00:00 PDT
The Lymphoma Research Foundation (LRF) has released a new mantle cell lymphoma (MCL) cell line, JeKo-1, in its MCL Cell Bank. The cell line, JeKo-1, was originated by Dr. H.J. Jeon of Chosun University, South Korea with attainment graciously assisted by Dr. Elias Campo, Hospital Clinic-Universitat, Barcelona, a member of LRF's Mantle Cell Consortium.
Sunesis Pharmaceuticals Reports Data From Nonclinical Studies Of SNS-032 At The Annual Meeting Of The American Association For Cancer Research published
Thu, 17 Apr 2008 00:00:00 PDT
Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) reported data from nonclinical studies of SNS-032 in multiple myeloma and mantle cell lymphoma. Data from studies conducted in collaboration with the Multiple Myeloma Research Consortium (MMRC) and with the University of Texas MD Anderson Cancer Center were presented at the Annual Meeting of the American Association for Cancer Research (AACR) in San Diego, CA.
Medarex Reports Phase 1/2 Clinical Data Of MDX-060 In Lymphoma At American Association For Cancer Research Meeting published
Thu, 17 Apr 2008 00:00:00 PDT
Medarex, Inc. (Nasdaq: MEDX) announced data from a Phase 1/2 trial that suggest a potential association between higher doses of MDX-060, an investigational anti-CD30 antibody, and improvement in disease control and prolonged progression-free survival in patients with relapsed or refractory CD30- positive lymphomas.
SuperGen Identifies Lead PIM Kinase Inhibitor, SGI-1776, That Causes Tumor Regression In AML Xenograft Models published
Thu, 17 Apr 2008 00:00:00 PDT
SuperGen Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies, announced as part of a series of presentations at the 2008 AACR Annual Meeting that that it has identified a lead PIM kinase inhibitor, SGI-1776, that causes tumor regression in acute myologenous leukemia (AML) xenograft models (Abstract No. 4974).
New Therapies That Could Change Treatment Strategies published
Wed, 16 Apr 2008 07:00:00 PDT
New drug compounds, and old ones put to new use, offer doctors and patients new hope for treating and preventing cancer. Studies presented at the 2008 Annual Meeting of the American Association for Cancer Research, April 12-16, show promise and progress against brain, colorectal, rectal and ovarian cancers and lymphoma.
St. Jude Gene Study Reveals Basis Of Anti Cancer Drug Resistance In Childhood Leukemia published
Wed, 16 Apr 2008 00:00:00 PDT
The first analysis of the genetic determinants of resistance to the anti-cancer drug methotrexate in childhood acute lymphoblastic leukemia (ALL) could offer a pathway to predicting such resistance and treatments to overcome it, according to a St. Jude Children's Research Hospital study. Besides its use in ALL, methotrexate is widely used to treat other cancers and some autoimmune diseases.
Regulating Hematopoietic Stem Cell Homeostasis And Leukemogenesis published
Tue, 15 Apr 2008 05:00:00 PDT
In the April 15th issue of G&D, Dr. Richard Flavell (Yale University) and colleagues identify the c-Cbl protein as a critical repressor of hematopoietic stem cell (HSC) self-renewal. In addition to establishing a key role for protein ubiquitylation in HSC development, this finding posits c-Cbl as a potential target in research into stem cell engineering as well as cell-based leukemia treatments.Dr.
Scientists Solve Arsenic's Cancer Paradox published
Tue, 15 Apr 2008 04:00:00 PDT
Cancer Research UK scientists have discovered how arsenic works as an effective treatment for leukaemia - according to a report in Nature Cell Biology* . Patients with a certain kind of leukaemia - acute promyelocytic leukaemia - can be successfully treated with arsenic**, but scientists didn't know how the process worked.
Discovery Offers New Avenues To Understanding An Aggressive Form Of Leukemia published
Tue, 15 Apr 2008 03:00:00 PDT
Researchers at St. Jude Children's Research Hospital have discovered evidence that a series of genetic mutations work together to initiate most cases of an aggressive and often-fatal form of acute lymphoblastic leukemia (ALL).These defects, known as "cooperating oncogenic lesions," include the deletion of a gene, IKZF1, whose protein, Ikaros, normally helps guide the development of a blood stem cell into a lymphocyte.
Arsenic And Leukaemia published
Tue, 15 Apr 2008 01:00:00 PDT
"Scientists solve riddle of arsenic cancer treatment" is the headline in The Guardian today. Although arsenic is poisonous and has been associated with an increased risk of cancer, paradoxically, "compounds of the metal have also been used to treat leukaemia" in the past, the newspaper adds, and it is still used to treat one form of the disease: acute promyelocytic leukaemia.
Micromet Presents Safety And Efficacy Data From Primate Studies With Two New BiTE Antibodies Developed For Treatment Of Leukaemia And Melanoma published
Tue, 15 Apr 2008 00:00:00 PDT
Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel antibodies for the treatment of cancer, inflammation and autoimmune diseases, presented at the Annual Meeting of the American Association for Cancer Research (AACR) in San Diego, CA, preclinical data of two new human BiTE(R) antibodies targeting CD33 and MCSP, for the treatment of acute myelogenous leukaemia (AML) and melanoma (1).
Genitope Corporation's MyVax(R) Personalized Immunotherapy Pivotal Phase 3 Trial Results Available On Company Website published
Fri, 11 Apr 2008 03:00:00 PDT
Genitope Corporation (Genitope, NASDAQ: GTOP) announced that a summary of the data from its pivotal Phase 3 clinical trial examining the use of MyVax® personalized immunotherapy (MyVax) in previously untreated follicular B-cell non-Hodgkin's lymphoma (fNHL) patients is available on the Investor Relations section of Genitope's Web site at http://ir.genitope.com. In December 2007, Genitope obtained data indicating that its pivotal Phase 3 clinical trial did not meet its primary endpoint.
)
|
|
